Group One Trading’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-593
| Closed | -$2K | – | 5670 |
|
|
2017
Q4 | $2K | Sell |
593
-7
| -1% | -$29 | ﹤0.01% | 4726 |
|
|
2017
Q3 | $2K | Buy |
+600
| New | +$2.29K | ﹤0.01% | 4680 |
|
|
2017
Q2 | – | Sell |
-131
| Closed | -$520 | – | 5380 |
|
|
2017
Q1 | $1K | Sell |
131
-2,754
| -95% | -$11.6K | ﹤0.01% | 4548 |
|
|
2016
Q4 | $12K | Sell |
2,885
-3,137
| -52% | -$20.3K | ﹤0.01% | 3904 |
|
|
2016
Q3 | $59K | Buy |
+6,022
| New | +$42.7K | ﹤0.01% | 3261 |
|
|
2016
Q1 | – | Sell |
-1,369
| Closed | -$10.5K | – | 5286 |
|
|
2015
Q4 | $18K | Sell |
1,369
-5,039
| -79% | -$86.8K | ﹤0.01% | 3975 |
|
|
2015
Q3 | $105K | Sell |
6,408
-13,157
| -67% | -$270K | ﹤0.01% | 3008 |
|
|
2015
Q2 | $439K | Buy |
19,565
+16,501
| +539% | +$261K | 0.01% | 1895 |
|
|
2015
Q1 | $30K | Sell |
3,064
-5,794
| -65% | -$56.8K | ﹤0.01% | 3686 |
|
|
2014
Q4 | $101K | Sell |
8,858
-5,057
| -36% | -$54.9K | ﹤0.01% | 2834 |
|
|
2014
Q3 | $160K | Buy |
13,915
+6,055
| +77% | +$92.5K | ﹤0.01% | 2567 |
|
|
2014
Q2 | $153K | Buy |
7,860
+4,182
| +114% | +$73.8K | ﹤0.01% | 2625 |
|
|
2014
Q1 | $66K | Sell |
3,678
-28,599
| -89% | -$470K | ﹤0.01% | 3426 |
|
|
2013
Q4 | $341K | Buy |
32,277
+7,559
| +31% | +$84.5K | 0.01% | 1965 |
|
|
2013
Q3 | $306K | Sell |
24,718
-1,256
| -5% | -$13.2K | 0.01% | 2021 |
|
|
2013
Q2 | $243K | Buy |
+25,974
| New | +$334K | 0.01% | 1992 |
|
Group One Trading's CASC Position: Q1 2018 in Review
Group One Trading sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 593 shares — an estimated $2K sold.
Group One Trading first reported a position in CASC in Q2 2013 and held it in 16 quarters. The position peaked at $439K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Group One Trading reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Group One Trading sold 593 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $2K.
- Group One Trading first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
- Group One Trading's Cascadian Therapeutics, Inc. position peaked at $439K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Group One Trading's 13F filing for Q1 2018, filed 11 May 2018.